CEDAR KNOLLS, N.J.,
Dec. 13, 2018 /PRNewswire/
-- MYOS RENS Technology Inc. ("MYOS" or "the Company")
(NASDAQ: MYOS), a biotherapeutics and bionutrition company and the
owner of Fortetropin®, a proprietary bioactive
composition derived from fertilized egg yolk that helps build lean
muscle, announced the results from the Company's Annual Meeting of
Stockholders held today. At the meeting, each of the following
proposals were approved and adopted:
- the re-election of Dr. Robert
Hariri and Ren Ren, each a
current Class I director, and the election of Eric Zaltas, each to serve until the 2021 Annual
Meeting of Stockholders;
- the appointment of WithumSmith+Brown, PC as the Company's
independent registered public accounting firm for the fiscal year
ending December 31, 2018
Eric Zaltas is the founder and
Chief Executive Officer of Pivot Nutrition LLC, a startup company
focused on researching, developing and distributing products for
various brands targeting athletes. Mr. Zaltas was previously Vice
President of R&D and Commercialization at Premier Nutrition
Corporation, a division of Post Holdings, Inc. from 2014 to 2018
where he led the integration of the R&D teams, pipelines and
innovation processes for both the Premier and PowerBar(s)
teams.
Joseph Mannello, Chief Executive
Officer of MYOS, commented, "Eric will be a strong addition to our
board of directors, bringing incomparable expertise and diverse
R&D and commercial experience. He is the perfect fit for MYOS
and we're fortunate to have him join our board at this critical
time."
Mr. Zaltas holds a B.S. degree in Geophysics from the
State University of New York at
Stony Brook and a M.S. degree in
Human Nutrition from the University of New
Haven. He also received a Diploma in Sports Nutrition from
the International Olympic Committee based in Lausanne, Switzerland.
"I'm excited to be a part of the MYOS team at such a pivotal
time, following the successful launch of MYOS Canine Muscle
Formula, and as the company launches its compelling sports
nutrition brand, Yolked®, which is
currently making great strides on college campuses," said Mr.
Zaltas.
About MYOS RENS Technology Inc.
MYOS RENS
Technology Inc. (Nasdaq: MYOS), "The Muscle Company®",
is a Cedar Knolls, NJ-based
bionutrition company that develops and markets products that
improve muscle health and performance. MYOS is the owner of
Fortetropin®, a fertilized egg yolk-based product
manufactured via a proprietary process to retain and optimize its
biological activity. Fortetropin has been clinically shown to
increase muscle size and lean body mass in conjunction with
resistance training. MYOS believes Fortetropin has the potential to
redefine existing standards of physical health and wellness. For
more information, please visit www.MYOSRENS.com.
Forward-Looking Statements
Any statements in
this release that are not historical facts are forward-looking
statements. Actual results may differ materially from those
projected or implied in any forward-looking statements. Such
statements involve risks and uncertainties, including but not
limited to those relating to product and customer demand, market
acceptance of our products, the ability to create new products
through research and development, the successful results of
strategic initiatives, the success of our products, including
Qurr®, Yolked®, MYOS
Enteral Nutrition Formula® and
MYOS Canine Muscle Formula™, the success of our research and
development, the results of the clinical evaluation of
Fortetropin® and its effects, the ability to enter into
new partnership opportunities and the success of our existing
partnerships, the ability to generate the forecasted revenue stream
and cash flow from sales of our products, the ability to increase
our revenue and gross profit margins, the ability to achieve a
sustainable, profitable business, the effect of economic
conditions, the ability to protect our intellectual property
rights, competition from other providers and products, the
continued listing of our securities on the Nasdaq Stock Market,
risks in product development, our ability to raise capital to fund
continuing operations, and other factors discussed from time to
time in our filings with the Securities and Exchange
Commission. We undertake no obligation to update or revise any
forward-looking statement for events or circumstances after the
date on which such statement is made except as required by
law.
These statements have not been evaluated by the Food and Drug
Administration. Our products are not intended to diagnose, treat,
cure or prevent any disease.
Investor Relations:
Porter LeVay & Rose
Michael Porter, President
Phone: 212-564-4700
Email: MYOS@plrinvest.com
View original content to download
multimedia:http://www.prnewswire.com/news-releases/myos-rens-technology-announces-results-of-its-2018-annual-meeting-of-stockholders-300765363.html
SOURCE MYOS RENS Technology